The 5mg Semaglutide Dose: Reading the Dosing Chart at This Stage

What 5mg actually refers to in a semaglutide dosing chart

This is the decision most people arrive at slightly confused, and the confusion is understandable. The licensed Wegovy injection schedule does not include a 5mg dose step. The standard weekly doses, as set out by Novo Nordisk and confirmed by the NHS, are 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg, titrated roughly every four weeks by your prescriber. A 5mg figure appears in two other contexts worth knowing about.

First, some syringe-drawn or compounded semaglutide preparations describe their concentration as 5mg per ml, which tells you about the liquid's strength, not the dose injected per week. Second, international discussions (particularly from the United States) sometimes reference different dosing conventions. If you have seen a chart listing 5mg as a weekly dose, it almost certainly does not describe a licensed UK product. The semaglutide 5mg page covers this distinction in more detail, including why concentration labelling and weekly dosing are not the same number. Getting this right matters: injecting based on a concentration figure rather than a prescribed weekly dose is one of the more serious risks associated with unlicensed preparations.

Licensed Wegovy, dispensed through a GPhC-registered pharmacy, arrives as a pre-filled pen with the dose pre-set. You do not calculate anything. That design choice removes a category of error entirely.

The decision the dosing chart is really helping you make

A dosing chart for semaglutide is less a rigid timetable and more a map of what your prescriber is weighing up at each review. The central question at every step is the same: is this person tolerating the current dose well enough to move up, and do the clinical signals suggest they should? Tolerance and response both matter.

The 2.5mg starting dose is the body's introduction to the medicine. By the time a prescriber considers moving someone forward, they want to see that nausea, vomiting, or other gastrointestinal effects have settled to a manageable level. If they have not, holding the current dose for another four weeks is entirely normal clinical practice, it is not a setback. The Wegovy dose guide explains each step and what the prescriber is looking for before progressing.

NICE's appraisal of semaglutide for weight management (NICE technology appraisal TA875) notes that if a patient achieves less than 5% weight loss after six months on the maintenance dose, continuing treatment should be reconsidered. That threshold exists at the maintenance end of the chart, not at interim steps. At 5mg equivalent concentrations or early titration stages, the focus is tolerance and adjustment, not outcome review.

Gastrointestinal effects and the 5mg/ml concentration risk

Whether someone is on a licensed 0.5mg or 1mg Wegovy step, or has encountered a 5mg/ml unlicensed preparation, the side-effect profile of semaglutide follows the same general pattern. Nausea is the most commonly reported effect, particularly after a dose increase. Vomiting, loose stools, constipation, indigestion, and fatigue are also well-documented. The NHS semaglutide medicines page lists these clearly and explains the circumstances that warrant medical attention, persistent severe stomach pain that moves toward the back, signs of dehydration, or an allergic reaction all need prompt assessment.

With unlicensed 5mg/ml vials, there is an additional layer of risk: the concentration must be converted to a volume for each injection, which introduces the possibility of calculation errors and, critically, means you cannot verify that what is in the vial is what the label claims. The MHRA has flagged this category of products specifically. Reporting suspected unsafe sellers through the Yellow Card scheme is how the regulator tracks these patterns.

One practical habit worth building at any dose: before each weekly injection, check the pen or vial against your prescription. The dose, the expiry date, and the appearance of the solution (clear and colourless, no particles) should all match what your prescriber issued. That takes under a minute and catches problems before they become one.

How a prescriber reviews your dose and what comes next

If you are on a licensed Wegovy prescription, your dose does not change without clinical re-review. At nume, that review happens before any repeat is dispatched, a qualified prescriber reads your clinical update, not an automated system. The Wegovy overview explains the full treatment pathway, and the semaglutide dosage chart walks through what each dose step is intended to do.

Cost is sometimes a factor in how people think about dosing, staying at a lower step for longer to reduce spend, for instance. The Wegovy price comparison guide addresses this honestly: treatment cost varies by dose and provider, and a prescriber's recommendation on timing should not be overridden by price calculations. The dose your prescriber recommends is based on your clinical picture.

If you are considering starting treatment and want to understand which option fits your situation, starting a free consultation puts your case in front of a GPhC-registered Independent Prescriber who can review your history and advise on the right path. There is no obligation and no algorithm involved.